Cytokinetics CYTK Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's operating lease liabilities?
- Cytokinetics (CYTK) reported operating lease liabilities of $105.24M in Q1 2026.
- How has Cytokinetics's operating lease liabilities changed year-over-year?
- Cytokinetics's operating lease liabilities decreased by 7.2% year-over-year, from $113.35M to $105.24M.
- What is the long-term trend for Cytokinetics's operating lease liabilities?
- Over 5 years (2020 to 2025), Cytokinetics's operating lease liabilities has grown at a 200.6% compound annual growth rate (CAGR), from $440K to $107.97M.
- What does operating lease liabilities mean?
- The long-term portion of the company's obligations for rented facilities and equipment.
- How do you interpret operating lease liabilities?
- An increase indicates expansion of physical footprint or longer lease terms, while a decrease suggests lease expirations or downsizing.
- How does operating lease liabilities compare across companies?
- Biotech peers typically carry significant lease liabilities due to specialized laboratory space requirements.